Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
30 déc. 2021 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind,...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
23 nov. 2021 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
12 nov. 2021 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis (NASH) and fibrosis, identified using non-invasive tests,...
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
12 nov. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of...
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
01 nov. 2021 16h01 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021...
Cardiometabolic Diseases Market Size ($121,804.49Mn by 2028) Lead by Cardiovascular Disease (3.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 09h54 HE
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cardiometabolic Diseases Market: Key InsightsAccording to our new research study on Cardiometabolic Diseases Market Size and Forecast to 2028 - COVID-19...
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
04 oct. 2021 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Kizoo Portfolio Company Underdog Closes $10M Financing Round
23 sept. 2021 07h00 HE
|
KIZOO Technology Capital GmbH
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital....
Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease
23 sept. 2021 02h00 HE
|
Draupnir Bio
Press Release Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen, Denmark, 23 September 2021 – Draupnir Bio...
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
08 sept. 2021 11h00 HE
|
Underdog Pharmaceuticals Inc.
MOUNTAIN VIEW, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related...